Drug Therapy, Combination
"Drug Therapy, Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapy with two or more separate preparations given for a combined effect.
| Descriptor ID |
D004359
|
| MeSH Number(s) |
E02.319.310
|
| Concept/Terms |
Drug Therapy, Combination- Drug Therapy, Combination
- Combination Chemotherapy
- Drug Polytherapy
- Drug Polytherapies
- Polytherapies, Drug
- Polytherapy, Drug
- Therapy, Combination Drug
- Chemotherapy, Combination
- Chemotherapies, Combination
- Combination Chemotherapies
- Combination Drug Therapy
- Combination Drug Therapies
- Drug Therapies, Combination
- Therapies, Combination Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Therapy, Combination".
Below are MeSH descriptors whose meaning is more specific than "Drug Therapy, Combination".
This graph shows the total number of publications written about "Drug Therapy, Combination" by people in this website by year, and whether "Drug Therapy, Combination" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 3 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 4 | 4 |
| 2004 | 2 | 4 | 6 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 11 | 11 |
| 2011 | 0 | 9 | 9 |
| 2012 | 0 | 8 | 8 |
| 2013 | 0 | 10 | 10 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 15 | 15 |
| 2016 | 1 | 11 | 12 |
| 2017 | 0 | 10 | 10 |
| 2018 | 0 | 12 | 12 |
| 2019 | 0 | 14 | 14 |
| 2020 | 0 | 6 | 6 |
| 2021 | 2 | 10 | 12 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 4 | 4 |
| 2024 | 0 | 8 | 8 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Therapy, Combination" by people in Profiles.
-
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025 Mar; 31(3):467-476.
-
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. Lancet Glob Health. 2025 Feb; 13(2):e355-e363.
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
-
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
-
Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries. Nat Commun. 2024 May 10; 15(1):3947.
-
Two-drug regimens for the treatment of HIV in Africa. Lancet HIV. 2024 Jun; 11(6):e419-e426.
-
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15?years. Contemp Clin Trials. 2024 Jul; 142:107540.
-
Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrob Agents Chemother. 2024 May 02; 68(5):e0158323.
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.